GM Advisory Group’s Standard BioTools LAB Stock Holding History

GM Advisory Group’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-300,000	Closed	-$390K	–	358
2025 Q3	$390K	Buy	300,000 +100,000	+50%	+$131K	0.02%	218
2025 Q2	$240K	Hold	200,000	–	–	0.01%	263
2025 Q1	$216K	Hold	200,000	–	–	0.01%	248
2024 Q4	$350K	Buy	+200,000	New	+$373K	0.02%	195

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

GM Advisory Group's LAB Position: Q4 2025 in Review

GM Advisory Group sold out of Standard BioTools (LAB) in Q4 2025, closing a stake of 300,000 shares — an estimated $390K sold.

GM Advisory Group first reported a position in LAB in Q4 2024 and held it in 4 quarters. The position peaked at $390K in Q3 2025. 159 funds tracked by Wall St. Rank hold LAB as of Q4 2025.

GM Advisory Group reported no remaining Standard BioTools position as of Q4 2025 after selling out during the quarter.
GM Advisory Group sold 300,000 Standard BioTools shares in Q4 2025, an estimated $390K.
GM Advisory Group first reported a position in Standard BioTools in Q4 2024 and held it in 4 quarters.
GM Advisory Group's Standard BioTools position peaked at $390K in Q3 2025.
159 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2025.

Based on GM Advisory Group's 13F filing for Q4 2025, filed 13 Feb 2026.